New Trend Emerges: 'Casual' Users Seek Weight-Loss Drugs

Got story updates? Submit your updates here. ›

A new report profiles an emerging group of "casual" users of weight-loss drugs like Ozempic and Wegovy in New York. These mostly women, who are not obese or diabetic, are obtaining the injectable GLP-1 medications through unconventional channels like med spas and online distributors, then experimenting with microdoses to shed a few pounds. Some view the drugs as a tool for mood and self-image, cycling them on and off as needed.

Why it matters

The rise of "casual" GLP-1 drug use highlights growing demand for quick weight-loss solutions, even among those who don't meet clinical criteria. However, these medications can carry serious side effects, and their use outside of medical supervision raises safety concerns.

The details

The report focuses on a group of mostly women in New York who are obtaining GLP-1 drugs like Ozempic, Wegovy, and newer compounds through unconventional channels like med spas, Instagram distributors, and online compounders. These individuals are not obese or diabetic, but are using the injectable medications to lose relatively modest amounts of weight. Some are learning microdosing techniques from social media and treating the drugs like a cyclical tool for mood and self-image, rather than a medically-supervised weight-loss program.

• The report on this emerging trend was published on March 29, 2026.

What they’re saying

What’s next

Experts are likely to continue monitoring this emerging trend and its potential health implications, as the use of GLP-1 drugs outside of medical supervision raises safety concerns.